Drug Trial Radar · NCT06570798
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Aug 6, 2028
Study completion Aug 6, 2028
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
Conditions
- Systemic Lupus Erythematosus
- Active Refractory Rheumatoid Arthritis
Interventions
InebilizumabDrug
IV Infusion
BlinatumomabDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 to Week 52
- Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Serious TEAETime frame: Day 1 to Week 52
- Subprotocol B Part B Subgroup 1: Number of Participants With Complete Renal Response (CRR)Time frame: Week 52
- Subprotocol B Part B Subgroup 2: Number of Participants With Remission in SLE as Defined by Definition of Remission in SLE (DORIS)Time frame: Week 26
- Subprotocol C Part B: Percentage of Participants Achieving Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP) RemissionTime frame: Week 12
Locations
58 sites in 10 countries. Site status is shown where the registry gives one.
HonorHealth Research and Innovation Institute
Scottsdale, Arizona · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Vida Research Center
Hialeah, Florida · Terminated
Homestead Associates In Research Inc
Homestead, Florida · Terminated
Vitaly Clinical Research
Miami, Florida · Terminated
Bioresearch Partner Coral Terrace
South Miami, Florida · Recruiting
University Medical Center New Orleans
New Orleans, Louisiana · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Northwell Health
Great Neck, New York · Recruiting
Westchester Medical Center
Hawthorne, New York · Completed
Columbia University Medical Center
New York, New York · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
MetroHealth Medical Center
Cleveland, Ohio · Recruiting
The Metro Health System Main Campus
Cleveland, Ohio · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Prolato Clinical Research Center
Houston, Texas · Completed
Seattle Rheumatology Associates
Seattle, Washington · Recruiting
Linear Clinical Research Limited
Perth, Western Australia, Australia · Recruiting
Cliniques Universtaire Saint Luc Universite Catholique de Louvain
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, Belgium · Recruiting
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
Le Kremlin-Bicêtre, France · Recruiting
Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez
Lille, France · Recruiting
Centre Hospitalier Universitaire de Lyon- Hopital Edouard Herriot
Lyon, France · Recruiting
Centre Hospitalier Universitaire de Lyon - Hopital Edouard Herriot
Lyon Cédex 3, France · Recruiting
Hopital de la Conception
Marseille, France · Recruiting
Hopital Cochin
Paris, France · Recruiting
Hopital Bichat Claude Bernard
Paris, France · Terminated
Hopital Europeen Georges Pompidou
Paris, France · Recruiting
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil
Strasbourg, France · Recruiting
Centre Hospitalier Universitaire de Strasbourg - Hopital de Hautepierre
Strasbourg, France · Recruiting
Centre Hospitalier Universitaire de Toulouse - Hopital Purpan
Toulouse, France · Recruiting
Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil
Toulouse, France · Recruiting
Krankenhaus Porz am Rhein gGmbH
Cologne, Germany · Recruiting
Universitaetsklinikum Duesseldorf AoeR
Düsseldorf, Germany · Recruiting
Universitaetsklinikum Leipzig
Leipzig, Germany · Recruiting
Klinikum der LMU Muenchen
München, Germany · Completed
IRCCS Ospedale San Raffaele
Milan, Italy · Terminated
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.